Literature DB >> 28237286

Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation.

Daniela Poli1, Emilia Antonucci2, Vittorio Pengo3, Sophie Testa4, Gualtiero Palareti5.   

Abstract

Anticoagulation is recommended in patients with atrial fibrillation (AF) for stroke prevention, and the bleeding risk associated suggests the need for a bleeding risk stratification. HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio (INR), elderly >65 years, drugs/alcohol concomitantly) score includes "labile INR" referred to quality of anticoagulation. However, in naïve patients, this item is not available. In addition, stroke and bleeding risk prediction scores shared several risk factors. The aims of our study were as follows: (1) to evaluate if the HAS-BLED score in its refined form excluding "labile INR" (HAS-BED [hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, elderly, drugs/alcohol]) is still associated with bleeding risk and (2) to evaluate the predictive ability for bleeding of both stroke and bleeding prediction models. We followed an inception cohort of 4,579 patients with AF enrolled in the Survey on anticoagulaTed pAtients RegisTer (NCT02219984). Major bleeds were recorded. During follow-up (7,014 patient-years), 115 patients experienced a major bleeding (MB; rate 1.6 × 100 patient-years). Patients at high risk were better identified by HAS-BLED and HAS-BED scores with respect to CHADS2 (congestive heart failure, hypertension, age >75 years, diabetes, previous stroke or transient ischemic attack) and CHA2DS2VASc (congestive heart, failure, hypertension, age [>75 years], diabetes, stroke/transient ischemic attack, vascular disease, age [65 to 74 years], female gender). HAS-BLED has a slightly higher c value in comparison to CHADS2 and CHA2DS2VASc. However, among naïve patients, the predictive ability for hemorrhage of HAS-BED score is overlapping with CHADS2 and CHA2DS2VASc. In low stroke risk patients (CHA2DS2VASc = 0 to 1), only 6 patients are at high bleeding risk, and none of them experienced MB. In conclusion, in our prospective cohort of patients with AF, we found that HAS-BLED and HAS-BED scores identify patients at high bleeding risk. However, the predictive value for MB of HAS-BED used in naïve patients is similar to CHADS2 or CHA2DS2VASc, suggesting that stroke stratification scores could be sufficient for tailoring treatment.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28237286     DOI: 10.1016/j.amjcard.2016.12.007

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Ischemic Stroke and Bleeding: Clinical Benefit of Anticoagulation in Atrial Fibrillation After Intracerebral Hemorrhage.

Authors:  Robert J Stanton; Mark H Eckman; Daniel Woo; Charles J Moomaw; Mary Haverbusch; Matthew L Flaherty; Dawn O Kleindorfer
Journal:  Stroke       Date:  2020-01-31       Impact factor: 7.914

2.  Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D.

Authors:  Nicolae Done; Amanda M Roy; Yingzhe Yuan; Steven D Pizer; Adam J Rose; Julia C Prentice
Journal:  Health Serv Res       Date:  2018-11-11       Impact factor: 3.402

3.  Propensity score methods for comparative-effectiveness analysis: A case study of direct oral anticoagulants in the atrial fibrillation population.

Authors:  Giorgio Ciminata; Claudia Geue; Olivia Wu; Manuela Deidda; Noemi Kreif; Peter Langhorne
Journal:  PLoS One       Date:  2022-01-24       Impact factor: 3.752

4.  A Simple Logistic Regression Model for Predicting the Likelihood of Recurrence of Atrial Fibrillation Within 1 Year After Initial Radio-Frequency Catheter Ablation Therapy.

Authors:  Sixiang Jia; Haochen Mou; Yiteng Wu; Wenting Lin; Yajing Zeng; Yiwen Chen; Yayu Chen; Qi Zhang; Wei Wang; Chao Feng; Shudong Xia
Journal:  Front Cardiovasc Med       Date:  2022-01-27

5.  Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism.

Authors:  Behnood Bikdeli; David Jiménez; Jorge Del Toro; Gregory Piazza; Agustina Rivas; José Luis Fernández-Reyes; Ángel Sampériz; Remedios Otero; José María Suriñach; Carmine Siniscalchi; Javier Miguel Martín-Guerra; Joaquín Castro; Alfonso Muriel; Gregory Y H Lip; Samuel Z Goldhaber; Manuel Monreal
Journal:  J Am Heart Assoc       Date:  2021-08-28       Impact factor: 5.501

6.  Management of Thrombosis Risk in a Carrier of Hemophilia A with Low Factor VIII Levels with Atrial Fibrillation: A Clinical Case and Literature Review.

Authors:  Nigel P Murray; Lorena Muñoz; Simona Minzer; Marco Antonio Lopez
Journal:  Case Rep Hematol       Date:  2018-09-05

7.  Anticoagulation strategies in critical care for the treatment of atrial fibrillation: a protocol for a systematic review and meta-analysis.

Authors:  Brian Johnston; Alexandra Nelson; Alicia C Waite; Gedeon Lemma; Ingeborg Welters
Journal:  BMJ Open       Date:  2020-10-20       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.